Allopurinol Attenuates Oxidative Stress and Cardiac Fibrosis in Angiotensin II-Induced Cardiac Diastolic Dysfunction

Cardiovascular Therapeutics

Volumn 30, Issue 2, 2012, Pages 117-123

  Jia, Nan ^a,b   Dong, Peixin ^c   Ye, Ying ^a   Qian, Cheng ^b   Dai, Qiuyan ^b  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SHANGHAI FIRST PEOPLE S HOSPITAL   (China)

^c FUDAN UNIVERSITY   (China)

Author keywords

Allopurinol; Diastolic dysfunction; Fibrosis; Oxidative stress; TGF 1

Indexed keywords

ALLOPURINOL; ANGIOTENSIN II; GLUTATHIONE; MALONALDEHYDE; MESSENGER RNA; SMAD3 PROTEIN; SMAD7 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DIASTOLIC DYSFUNCTION; DOWN REGULATION; DRUG EFFECT; HEART MUSCLE FIBROSIS; HEART RATE; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SYSTOLIC BLOOD PRESSURE; UPREGULATION;

ALLOPURINOL; ANGIOTENSIN II; ANIMALS; BLOOD PRESSURE; DIASTOLE; ELECTROCARDIOGRAPHY; ENZYME INHIBITORS; FIBROSIS; HEART DISEASES; HEART FAILURE, DIASTOLIC; HEART FUNCTION TESTS; HEART RATE; MALE; MICE; MICE, INBRED C57BL; MYOCARDIUM; OXIDATIVE STRESS; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; SMAD PROTEINS; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84858234927     PISSN: 17555914     EISSN: 17555922     Source Type: Journal    
DOI: 10.1111/j.1755-5922.2010.00243.x     Document Type: Article

References (26)

1. Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure. Part I: Diagnosis, prognosis, and measurements of diastolic function. Circulation 2002;105:1387-1393.
2. Matsui Y, Jia N, Okamoto H, et al. Role of osteopontin in cardiac fibrosis and remodeling in angiotensin II-induced cardiac hypertrophy. Hypertension 2004;43:1195-1201.
3. Sawyer DB, Siwik DA, Xiao L, Pimentel DR, Singh K, Colucci WS. Role of oxidative stress in myocardial hypertrophy and failure. J Mol Cell Cardiol 2002;34:379-388.
4. Engberding N, Spiekermann S, Schaefer A, et al. Allopurinol attenuates left ventricular remodeling and dysfunction after experimental myocardial infarction: A new action for an old drug Circulation 2004;110:2175-2179.
5. Shi Y, Evans JE, Rock KL. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 2003;425:516-521.
6. Numaguchi K, Egashira K, Takemoto M, Kadokami T, Shimokawa H, Sueishi K, Takeshita A. Chronic inhibition of nitric oxide synthesis causes coronary microvascular remodeling in rats. Hypertension 1995;26:957-962.
7. Sam F, Xie Z, Ooi H, Kerstetter DL, Colucci WS, Singh M, Singh K. Mice lacking osteopontin exhibit increased left ventricular dilation and reduced fibrosis after aldosterone infusion. Am J Hypertens 2004;17:188-193.
8. Dhalla AK, Hill MF, Singal PK. Role of oxidative stress in transition of hypertrophy to heart failure. J Am Coll Cardiol 1996;28:506-514.
9. Oudit GY, Trivieri MG, Khaper N, et al. Taurine supplementation reduces oxidative stress and improves cardiovascular function in an iron overload murine model. Circulation 2004;109:1877-1885.
10. Amado LC, Saliaris AP, Raju SV, et al. Xanthine oxidase inhibition ameliorates cardiovascular dysfunction in dogs with pacing-induced heart failure. J Mol Cell Cardiol 2005;39:531-536.
11. Hayashi K, Kimata H, Obata K, et al. Xanthine oxidase inhibition improves left ventricular dysfunction in dilated cardiomyopathic hamsters. J Card Fail 2008;14:238-244.
12. Naumova AV, Chacko VP, Ouwerkerk R, Stull L, Marbán E, Weiss RG. Xanthine oxidase inhibitors improve energetics and function after infarction in failing mouse hearts. Am J Physiol Heart Circ Physiol 2006;290:837-843.
13. Mellin V, Isabelle M, Oudot A, et al. Transient reduction in myocardial free oxygen radical levels is involved in the improved cardiac function and structure after long-term allopurinol treatment initiated in established chronic heart failure. Eur Heart J 2005;15:1544-1550.
14. Bendall JK, Cave AC, Heymes C, Gall N, Shah AM. Pivotal role of a gp91(phox)-containing NADPH oxidase in angiotensin II-induced cardiac hypertrophy in mice. Circulation 2002;105:293-296.
15. Touyz RM, Mercure C, He Y, et al. Angiotensin II-dependent chronic hypertension and cardiac hypertrophy are unaffected by gp91phox-containing NADPH oxidase. Hypertension 2005;45:530-537.
16. Kinugawa S, Tsutsui H, Hayashidani S, et al. Treatment with dimethylthiourea prevents left ventricular remodeling and failure after experimental myocardial infarction in mice: Role of oxidative stress. Circ Res 2000;87:392-398.
17. Ceconi C, Bernocchi P, Boraso A, Cargnoni A, Pepi P, Curello S, Ferrari R. New insights on myocardial pyridine nucleotides and thiol redox state in ischemia and reperfusion damage. Cardiovasc Res 2000;47:586-594.
18. Meister A. Glutathione deficiency produced by inhibition of its synthesis, and its reversal; applications in research and therapy. Pharmacol Ther 1991;51: 155-194.
19. Ceconi C, Cargnoni A, Pasini E, Condorelli E, Curello S, Ferrari R. Evaluation of phospholipid peroxidation as malondialdehyde during myocardial ischemia and reperfusion injury. Am J Physiol 1991;260:1057-1061.
20. Khan R, Sheppard R. Fibrosis in heart disease: Understanding the role of transforming growth factor-beta in cardiomyopathy, valvular disease and arrhythmia. Immunology 2006;118:10-24.
21. Rosenkranz S. TGF-beta1 and angiotensin networking in cardiac remodeling. Cardiovasc Res 2004;63:423-432.
22. Wang B, Hao J, Jones SC, Yee MS, Roth JC, Dixon IM. Decreased Smad 7 expression contributes to cardiac fibrosis in the infarcted rat heart. Am J Physiol Heart Circ Physiol 2002;282:1685-1696.
23. Kawano H, Do YS, Kawano Y, Starnes V, Barr M, Law RE, Hsueh WA. Angiotensin II has multiple profibrotic effects in human cardiac fibroblasts. Circulation 2000;101:1130-1137.
24. Kuwahara F, Kai H, Tokuda K, Kai M, Takeshita A, Egashira K, Imaizumi T. Transforming growth factor-β function blocking prevents myocardial fibrosis and diastolic dysfunction in pressure-overloaded rats. Circulation 2002;106:130-135.
25. Derynck R, Zhang YE. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 2003;425:577-584.
26. Verrecchia F, Pessah M, Atfi A, Mauviel A. Tumor necrosis factor-α inhibits transforming growth factor-β/Smad signaling in human dermal fibroblasts via AP-1 activation. J Biol Chem 2000;275:30226-30231.